Eckert & Ziegler stock gains after H1 2026 margins improve

Published on 09/10/2026 at 16:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eckert & Ziegler stock closed at EUR 12.54 on Xetra on September 9, 2026, up around 1.0 percent from the prior day. H1 2026 revenue was nearly flat at about EUR 149.3 million, while net profit and margins improved versus a year earlier.

Photorealistischer Reinraum einer radiopharmazeutischen Produktionsanlage — Eckert & Ziegler DE0005659700 Medizintechnik: Forscher arbeiten in modernem Radiopharmazeutika-Reinraum mit Gloveboxen und Hot-Cells, Illustration mit AI erstellt.

Eckert & Ziegler stock (ISIN DE0005659700) closed at 12.54 euros on Xetra on September 9, 2026, marking a daily increase of 1.0 percent compared with the previous trading day and ending the session near the upper end of its intraday range between roughly 12.40 and 12.60 euros.

Half-year 2026 results underpin recent move

For the first half of 2026, Eckert & Ziegler reported revenue of around 149.3 million euros, essentially unchanged year over year, as growth in radiopharmaceuticals offset a weaker product mix in the Isotope Products segment, according to Quartr on August 13, 2026.

Net profit in H1 2026 rose 4.5 percent to 22.4 million euros, while earnings per share increased to 0.36 euros, reflecting better margins in the Medical segment and favorable currency effects, as summarized by Quartr for the same period.

The company’s adjusted EBIT margin stood at 22 percent in H1 2026, down from 24 percent a year earlier, indicating some margin pressure in parts of the business even as profitability in Medical improved, according to Quartr.

Radiopharmaceutical growth versus isotope headwinds

Within the portfolio, radiopharmaceuticals delivered solid growth in the first half of 2026, with segment revenue up around 3 percent year over year and underlying growth higher once license effects are adjusted out, as described by Quartr.

By contrast, the Isotope Products segment saw adjusted EBIT decline and margin compression, with the overall adjusted EBIT margin falling from 24 percent to 22 percent year over year, highlighting the impact of an unfavorable product mix, according to Quartr.

For investors, the contrast between rising Medical segment margins and weaker isotope economics is central to the story: Medical segment EBIT margin reached around 31 percent versus 13 percent for Isotope Products, underscoring where the company’s profitability is concentrated, as summarized by Quartr.

Guidance and balance sheet support medium-term story

Eckert & Ziegler has maintained its full-year 2026 guidance at 320 million euros in revenue and 80 million euros in adjusted EBIT, signaling management’s confidence in a stronger second half, according to Quartr on August 13, 2026.

The company’s investor-relations overview reports revenue of 312.0 million euros for fiscal year 2025 and adjusted EBIT of 77.7 million euros for that year, providing a historical baseline for the current 2026 targets, according to Eckert & Ziegler.

On the balance sheet side, cash and equivalents stood at about 110.2 million euros at the end of H1 2026, with loan liabilities around 10 million euros, leaving the company close to debt-free and offering flexibility to support growth in radiopharmaceuticals, according to data compiled by Quartr.

Next earnings date and investor checkpoints

The next scheduled earnings event for Eckert & Ziegler is the third-quarter 2026 report, with an earnings date listed as November 12, 2026, according to Quartr.

In the meantime, management expects underlying revenue growth of around 9 percent and adjusted EBIT growth of about 21 percent for full-year 2026 when currency and license effects are excluded, suggesting an acceleration versus the flat reported revenue in H1 2026, as outlined by Quartr.

Stock level on Xetra

As of the Xetra close on September 9, 2026, Eckert & Ziegler stock traded at 12.54 euros, with the day’s performance showing a 1.0 percent gain over the prior close and the price finishing toward the upper end of the intraday range between roughly 12.40 and 12.60 euros.